Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=27 Discontinuation From Chronic Opioid Therapy For Pain Using a Buprenorphine Taper
Chronic Pain · Opioid Pain Medication
Primary: Percentage of Patients Who Tolerate Buprenorphine Initiation — 27 Participants
N/A N=179 Motivational Interviewing and Guided Opioid Tapering Support to Promote Postoperative Opioid Cessation
Opioid Cessation
Primary: Time to Opioid Cessation — 28; 25 days
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
Phase 3 N=11 A Strategy to Improve Success of Treatment Discontinuation in Buprenorphine Responders
Opioid-use Disorder
Primary: Percent of Patients Successfully Transitioned Off Buprenorphine — 2; 3 Participants
N/A N=196 Discharge Opioid Education to Decrease Opioid Use After Cesarean
Opioid Use
Primary: Opioid Use — 7.5; 10 hydrocodone tablets
Phase 2 N=4 Benzodiazepine Discontinuation in Opioid Agonist Therapy
Substance Use Disorders
Primary: Participant Acceptability of the Interventions — 1; 0 Participants
N/A N=190 Opioid Prescribing After Cesarean Delivery
Surgery · Opioid Use
Primary: Unused Opioids — 5; 10 oxycodone 5mg tablets
N/A N=10 Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal
Substance-Related Disorders
Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001
N/A N=78 Behavioral and Enhanced Perinatal Intervention for Cessation (B-EPIC): Reducing Tobacco Use Among Opioid Addicted Women
Smoking Cessation
Primary: Change in the Number of Cigarettes Smoked Per Day — 0; 0 cigarettes per day
Phase 2 N=12 A Within Subject Comparison of Opioid Withdrawal in Opioid Dependent Individuals
Opioid Abuse · Opioid Dependence
Primary: Mean Peak Opioid Withdrawal Assessed by the Clinical Opiate Withdrawal Scale (COWS) — 12.6; 1.3 units on a scale
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
Phase 2 N=6 Nalrexone Facilitated Discontinuation of Buprenorphine
Stable Opioid Dependence
Primary: Successful Discontinuation of Buprenorphine — 6 Participants
N/A N=321 Subthreshold Opioid Use Disorder Prevention (STOP) Trial
Opioid-use Disorder
Primary: Days of Risky Opioid Use in Past 180 Days — 12.2; 15.5 days
Phase 4 N=112 Smoking Cessation Treatment for Methadone Maintenance Patients
Smoking Cessation · Substance-Related Disorders
Primary: Biochemically Verified Abstinence Verified With Expired Carbon Monoxide (CO) < 8 p.p.m. — 6; 0 participants — p=0.03
N/A N=100 Varenicline Smoking Cessation Treatment for Methadone Maintenance Patients
Tobacco Use Disorder · Medication Adherence
Primary: Varenicline Adherence as Measured by Pill Count — 61.8; 78.5 percentage pills taken/pills dispensed
Phase 2 N=16 Glutamatergic Modulation to Facilitate Naltrexone Initiation in Opioid Dependence
Opioid Dependence
Primary: Successful Naltrexone Initiation — 11 Participants
N/A N=7 Opioid Taper Study
Chronic Pain
Primary: Pain Perception Measured Using the Cold-pressor Test (CPT) — 24.01; 42.02 seconds
Phase 2 N=38 Medical Management of Sleep Disturbance During Opioid Tapering
Opioid Dependence · Opioid Withdrawal · Sleep Disturbance
Primary: Abuse Liability as Assessed by Visual Analogue Scale — 23.9; 20.9; 22.8 score on a scale*days — p=.950
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 3 N=117 Improving Treatment Outcomes for Prescription Opioid Dependence
Drug Dependence
Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77
N/A N=213 Single Session Class to Reduce Opioid Use in Chronic Pain
Chronic Pain
Primary: Opioid Use — -6.7; -8.0 MME — p=.89
Phase 4 N=113 Buprenorphine Maintenance vs. Detoxification in Prescription Opioid Dependence
Opiate Dependence
Primary: Illicit Opioid Use — 35.2; 53.2 percent of opioid negative urine samples
N/A N=115 Opioid Treatment and Recovery Through a Safe Pain Management Program
Depression · Opioid Use · Chronic Pain
Primary: Odds of Morphine Equivalent Daily Dose (MEDD) of Opioid Prescription >=50 mg — 0.209; 0.417; 0.185; 0.364 odds of prescription high dose — p=0.956
Phase 2 N=3 Oral Cannabidiol for Opioid Withdrawal
Opioid Withdrawal · Opioid Craving · Opioid Use Disorder
Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events
N/A N=15 Functional Magnetic Resonance Imaging of Opioid Withdrawal in Healthy Human Volunteers
Substance-Related Disorders
Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…
N/A N=211 TAU Opioid Use Outcomes Following Discharge From Detoxification and Short Term Residential Programs Affiliated With CTN-0051
Opioid Use Disorder
Primary: Days of Opioid Use — 6.8 days
Phase 3 N=53 Efficacy of Extended Release Tramadol for Treating Prescription Opioid Withdrawal
Substance Withdrawal Syndrome
Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale
Phase 3 N=5,521 Opioid Prescription After Cesarean Trial
Pregnancy Related · Opioid Use · Pain
Primary: Number of Participants With Worst Pain Score of Moderate to Severe on the Brief Pain Inventory — 1497; 1535 Participants
Phase 4 N=160 Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty
Joint Disease · Pain, Acute · Pain, Chronic
Primary: Opioid Use — 288; 432.5 Oral Morphine Equivalent (mg)